These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 26542609)

  • 21. Use of SATB2 and CDX2 Immunohistochemistry to Characterize and Diagnose Colorectal Cancer.
    Kato S; Koshino A; Lasota J; Komura M; Wang C; Ebi M; Ogasawara N; Kojima K; Tsuzuki T; Kasai K; Takahashi S; Miettinen M; Kasugai K; Inaguma S
    Appl Immunohistochem Mol Morphol; 2024 Sep; 32(8):362-370. PubMed ID: 39076030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
    Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
    J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.
    Vang R; Gown AM; Wu LS; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
    Mod Pathol; 2006 Nov; 19(11):1421-8. PubMed ID: 16980943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
    Dabir PD; Svanholm H; Christiansen JJ
    APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors.
    Ferreira CR; Carvalho JP; Soares FA; Siqueira SA; Carvalho FM
    Int J Gynecol Cancer; 2008; 18(1):59-65. PubMed ID: 17511804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of SATB2 immunostaining in the distinction between small intestinal and colorectal adenocarcinomas.
    Kim CJ; Baruch-Oren T; Lin F; Fan XS; Yang XJ; Wang HL
    J Clin Pathol; 2016 Dec; 69(12):1046-1050. PubMed ID: 27169755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diagnostic value of SATB2, CK7 and CK20 in colorectal cancer].
    Lyn J; Wang Y; Wang F; Shen M; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):578-81. PubMed ID: 26705182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
    Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
    Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms.
    Ciocca V; Bombonati A; Palazzo JP; Schulz S; Waldman SA
    Histopathology; 2009 Aug; 55(2):182-8. PubMed ID: 19694825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.
    Elias KM; Labidi-Galy SI; Vitonis AF; Hornick JL; Doyle LA; Hirsch MS; Cramer DW; Drapkin R
    Gynecol Oncol; 2014 Feb; 132(2):328-33. PubMed ID: 24342438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of REG4 in ovarian mucinous tumors.
    Huang Q; Chen X; Lu W; Lai M; Lu B
    Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):295-301. PubMed ID: 23958547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of SATB2 expression in colon cancer and its differential diagnosis in digestive tract adenocarcinoma and ovarian primary and metastatic carcinoma.
    Liu F; Gao Z; Shen D; Zhao H; Wang C; Ye Y; Ma Y; Kong F
    Pathol Res Pract; 2019 Jul; 215(7):152430. PubMed ID: 31101576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
    Ates Ozdemir D; Usubutun A
    Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours.
    Wang F; Yang Y; Du X; Zhu X; Hu Y; Lu C; Sui L; Zhao H; Song K; Yao Q
    BMC Cancer; 2023 Jan; 23(1):44. PubMed ID: 36639622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary ovarian carcinoid tumors may express CDX-2: a potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary.
    Rabban JT; Lerwill MF; McCluggage WG; Grenert JP; Zaloudek CJ
    Int J Gynecol Pathol; 2009 Jan; 28(1):41-8. PubMed ID: 19047909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours.
    Fraggetta F; Pelosi G; Cafici A; Scollo P; Nuciforo P; Viale G
    Virchows Arch; 2003 Dec; 443(6):782-6. PubMed ID: 14576939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin.
    Chou YY; Jeng YM; Kao HL; Chen T; Mao TL; Lin MC
    Histopathology; 2003 Aug; 43(2):151-6. PubMed ID: 12877730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffusely Metastasized Adenocarcinoma Arising in a Mucinous Carcinoid of the Ovary: A Case Report.
    Van Rompuy AS; Vanderstichele A; Vergote I; Moerman P
    Int J Gynecol Pathol; 2018 May; 37(3):290-295. PubMed ID: 28463910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrant expression of SATB2, CDX2, CDH17 and CK20 in hepatocellular carcinoma: a pathological, clinical and outcome study.
    Kmeid M; Lukose G; Hodge K; Cho D; Kim KA; Lee H
    Histopathology; 2021 Nov; 79(5):768-778. PubMed ID: 34036629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours.
    Hoskoppal D; Epstein JI; Gown AM; Arnold Egloff SA; Gordetsky JB; Shi CJ; Giannico GA
    Histopathology; 2020 Mar; 76(4):550-559. PubMed ID: 31595536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.